3531: The NARLAL II trial: First results on loco-regional control in stage 3 NSCLC

IF 4.9 1区医学 Q1 ONCOLOGY Radiotherapy and Oncology Pub Date : 2024-08-30 DOI:10.1016/s0167-8140(24)03438-8

Tine Schytte, Charlotte Kristiansen, Ane Appelt, Azza Khalil, Carsten Brink, Christina Maria Lutz, Ditte Slot Moeller, Erland Sande, Filippa Sundbye, Gitte Persson, Lone Hoffmann, Lotte Holm Land, Lotte Victoria Rogg, Mette Poehl, Mikkel Lund, Morten Nielsen, Nina Levin, olfred Hansen, Rune Slot Thing, Tarje Halvorsen, Tine Bjoern Nielsen, Torben Schjødt Hansen, Vilde Haakensen, Wiviann Ottosson, Marianne Knap

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

3531: NARLAL II 试验：3期NSCLC局部区域控制的首批结果

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Radiotherapy and Oncology 医学-核医学

CiteScore

10.30

自引率

10.50%

发文量

2445

审稿时长

45 days

期刊介绍： Radiotherapy and Oncology publishes papers describing original research as well as review articles. It covers areas of interest relating to radiation oncology. This includes: clinical radiotherapy, combined modality treatment, translational studies, epidemiological outcomes, imaging, dosimetry, and radiation therapy planning, experimental work in radiobiology, chemobiology, hyperthermia and tumour biology, as well as data science in radiation oncology and physics aspects relevant to oncology.Papers on more general aspects of interest to the radiation oncologist including chemotherapy, surgery and immunology are also published.